Clinical trial
A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
NCT01097746 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 14, 2010
- Completion date
- September 13, 2022
- Enrollment
- 33 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube carcinoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, figo stage iii ovarian cancer, figo stage iiia ovarian cancer, figo stage iiia1 ovarian cancer, figo stage iiia1(i) ovarian cancer, figo stage iiia1(ii) ovarian cancer, figo stage iiia2 ovarian cancer, figo stage iiib ovarian cancer, figo stage iiic ovarian cancer, figo stage iva ovarian cancer, figo stage ivb ovarian cancer, malignant ovarian brenner tumor, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal carcinoma, primary peritoneal serous adenocarcinoma